Abstracts tagged "Osteoarthritis"

Abstract Number: 32 • 2014 ACR/ARHP Annual Meeting
Regulation of Senescence and Inflammatory Mediators By N- and C-Terminal Parathyroid Hormone-Related Protein in Osteoarthritic Human Osteoblasts
Maria Isabel Guillén¹, Julia Platas¹, Sergio Portal-Nuñez², Pedro Esbrit³ and M.J. Alcaraz⁴, ¹Pharmacology, University of Valencia, Burjasot, Valencia, Spain, ²Metabolismo mineral y óseo, Fundación Jimenez Diaz, Madrid, Spain, ³Fundación Jimenez Diaz, Madrid, Spain, ⁴University of Valencia, Burjasot, Valencia, Spain
Background/Purpose In osteoarthritis (OA), there is an abnormal remodeling process in subchondral bone associated with an altered osteoblast metabolism. Inflammatory mediators participate in bone remodeling…
Abstract Number: 2947 • 2014 ACR/ARHP Annual Meeting
Adenosine a_2A Receptor As a Potential New Therapeutic Target for the Prevention/Treatment of Osteoarthritis
Carmen Corciulo¹, Aranzazu Mediero², Tuere Wilder³ and Bruce N. Cronstein⁴, ¹Division of Translational Medicine, Department of Medicine, NYU School of Medicine, New York, NY, ²Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ³Medicine, division of Translational Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Osteoarthritis results from trauma, mechanical factors or metabolic changes in bone and cartilage. Adenosine, acting via the A2AR, inhibits inflammation and plays a critical…
Abstract Number: 1021 • 2014 ACR/ARHP Annual Meeting
Transthyretin and Amyloid in Cartilage Aging and Osteoarthritis
Yukio Akasaki¹, Oscar Alvarez-Garcia¹, Natalia Reixach², Joel Buxbaum², Yukihide Iwamoto³ and Martin K. Lotz¹, ¹Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ²Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ³Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Background/Purpose Deposition of amyloid is a common aging-associated phenomenon and a key factor in the pathogenesis of several aging-related diseases. Osteoarthritis is the most prevalent…
Abstract Number: 2439 • 2014 ACR/ARHP Annual Meeting
Knee Joint Pathology in Patients with Rheumatoid Arthritis and Osteoarthritis Using a Validated Ultrasound Scoring System: A Cross Sectional Study
Karen Ellegaard¹, Marius Henriksen², Birgit Falk Riecke³, Søren Just⁴, Jakob Espesen⁵, Mohammed Yusuf Naderi⁶ and Henning Bliddal³, ¹Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ²Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, ³The Parker Institute, Copenhagen, Denmark, ⁴Department of Rheumatology, Svenborg Sygehus, Svendbotg, Denmark, ⁵Odense Universitetshospital, Odense, Denmark, ⁶Department of Rheumatology, Esbjerg Sygehus, Esbjerg, Denmark
Background/Purpose Ultrasound (US) signs of inflammation in joints are synovial hypertrophy, effusion, and Doppler activity (increased perfusion), which have been demonstrated in both osteoarthritis (OA)…
Abstract Number: 977 • 2014 ACR/ARHP Annual Meeting
Randomized Clinical Trial of a Patient and Provider Intervention for Managing Osteoarthritis in Veterans
Kelli D. Allen^1,2, Hayden B. Bosworth^3,4, Amy Jeffreys¹, Cynthia Coffman^3,5, Santanu Datta^4,6, Jennifer McDuffie^1,7, Eugene Oddone^3,4, Jennifer Strauss^1,8 and William S. Yancy Jr.^1,4, ¹Health Services Research, Durham VA Medical Center, Durham, NC, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Health Services Research, Durham VA Medical Center and Duke University Medical Center, Durham, NC, ⁴Department of Medicine, Division of General Internal Medicine, Duke University Medical Center, Durham, NC, ⁵Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, ⁶Health Services Reserach, Durham VA Medical Center and Duke University Medical Center, Durham, NC, ⁷Medicine, Duke University Medical Center, Durham, NC, ⁸Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
Background/Purpose: Adequate management of osteoarthritis (OA) requires both medical and behavioral strategies. However, some recommended therapies are under-utilized in clinical settings, and there is low…
Abstract Number: 2337 • 2014 ACR/ARHP Annual Meeting
The Cost and Effectiveness of Various Recruitment Strategies in a Mind Body Clinical Trial Among Older Adults with Knee Osteoarthritis
Jade V. Goldsmith¹, Lori Lyn Price², Jeffrey B. Driban³, William F. Harvey³ and Chenchen Wang³, ¹Center for Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, ²Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ³Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose : Recruitment and adherence are important and challenging factors that can determine the success of a clinical trial. Mind body therapies are an emerging and…
Abstract Number: 978 • 2014 ACR/ARHP Annual Meeting
Socioeconomic Status Measures Are Associated with Increasing Pain, Stiffness and Physical Function Among Individuals with Knee and Hip Osteoarthritis
Rebecca J. Cleveland¹, Jordan B. Renner², Joanne M. Jordan³ and Leigh F. Callahan⁴, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina Department of Radiology, Chapel Hill, NC, ³University of North Carolina Dept of Epidemiology, Chapel Hill, NC, ⁴Thurston Arthritis Res Ctr, University of North Carolina, Chapel Hill, NC
Background/Purpose The determinants of disability progression (DP) among those with knee and/or hip osteoarthritis (OA) are not well known. Our aim was to explore whether…
Abstract Number: 2233 • 2014 ACR/ARHP Annual Meeting
A PHASE 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy Study of Apremilast (CC-10004) in Subjects with Erosive Hand Osteoarthritis
Juergen Rech¹, Francesca Faustini¹, Axel J. Hueber¹, Wolfgang Ochs², Wolfgang Spieler³, Herbert Kellner⁴, Ulf Muller-Ladner⁵, Mathias Grünke⁶, Matthias Schneider⁷ and Georg Schett⁸, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Rheumatologist in private practice, Bayreuth, Germany, ³Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁴Centre for Inflammatory Joint Diseases, Munich, Germany, ⁵Internal Medicine/Rheumatology, Univ Giessen/Kerckhoff-Clinic, Bad Nauheim, Germany, ⁶Division of Rheumatology, University of Munich, Munich, Germany, ⁷Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose We report on a phase II, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study in subjects with erosive hand osteoarthritis. Subjects must have had…
Abstract Number: 922 • 2014 ACR/ARHP Annual Meeting
A Potential Role for TLR4 Activation in Osteoarthritis Associated Pain
Rachel E. Miller¹, Shingo Ishihara², Phuong Tran³, Richard J. Miller⁴ and Anne-Marie Malfait⁵, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁵Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose - Damage associated molecular patterns (DAMPs) result from cellular stress and extracellular matrix breakdown. They may contribute to osteoarthritis (OA) pathogenesis by promoting synovitis…
Abstract Number: 2237 • 2014 ACR/ARHP Annual Meeting
Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients
Susanne X. Wang¹, Jeroen Medema¹, Matthew Kosloski¹, Wei Liu¹, Mary Saltarelli¹ and Morten Asser Karsdal², ¹AbbVie Inc., North Chicago, IL, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) may comprise multiple phenotypes, one of which is inflammation-driven OA. Consequently, a selected subpopulation of OA patients may benefit from optimally targeted…
Abstract Number: 257 • 2014 ACR/ARHP Annual Meeting
Quality of Life Assessment of Adults Patients with X-Linked Hypophosphoremia
Karine Briot¹, Hélène Ché¹, Adrien Etcheto¹, Anya Rothenbuhler², Peter Kamenicky,², Agnès Linglart² and Christian Roux³, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Hôpital Bicêtre, Kremlin Bicêtre, France, ³Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose: X-Linked Hypophosphatemia (XLH) is the most common form of heritable rickets. Although disease severity is variable, adults with XLH may suffer from skeletal symptoms…
Abstract Number: 2243 • 2014 ACR/ARHP Annual Meeting
Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough?
Giuseppa Quartarone¹ and Nathalie Hasler-Nguyen², ¹Medical Affairs, Novartis CH R&D OU Italy Greece, Milan, Italy, ²Pre-Cinical Development, Novartis CH Global R&D, Nyon, Switzerland
Background/Purpose Topically applied non-steroidal anti-inflammatory drugs (NSAIDs) can produce clinically effective drug concentrations at a peripheral site, but with low systemic concentrations and thus a…
Abstract Number: 249 • 2014 ACR/ARHP Annual Meeting
A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes
Vibeke Strand¹, Allan Gibofsky², Marc Hochberg³, Roy Altman⁴, Byron Cryer⁵, Alan Kivitz⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹Stanford University, Palo Alto, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³University of Maryland School of Medicine, College Park, MD, ⁴University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA
Background/Purpose: Diclofenac is used for the treatment of osteoarthritis (OA), but, like other NSAIDs, it is associated with serious dose-related adverse events. The FDA has…
Abstract Number: 2247 • 2014 ACR/ARHP Annual Meeting
Bariatric Surgery Improves Quality of Life in Patients with Osteoarthritis and Obesity Compared to Non-Surgical Weight Loss
Christopher Chong¹, Sangeeta Kashyap², Philip Schauer², Colin O'Rourke³ and M. Elaine Husni⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, JJN3-01, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Numerous studies support obesity as a strong risk factor for development and progression of knee osteoarthritis (OA). The potential benefits of massive weight loss,…
Abstract Number: 222 • 2014 ACR/ARHP Annual Meeting
OA Phenotypes Rather Than Disease Stage Drive Structural Progression – Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA
Morten Asser Karsdal¹, Anne C. Bay-Jensen², Asger Bihlet³, Peter Alexandersen⁴, Inger Byrjalsen³, Bente J. Riis³ and Claus Christiansen³, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Center for Clinical and Basic Research, Vejle, Denmark
Background/Purpose: Osteoarthritis (OA) is a heterogeneous disorder, with several possible drivers of disease progression. Up to 50% of OA patients do not structurally progress, emphasizing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].